FGF6

Across TCGA pan-cancer cohorts, FGF6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated FGF6 data layer compared with 17 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher FGF6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FGF6 expression acts as an unfavorable survival marker.

LUSC, PAAD, and BLCA are the cancer types where FGF6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.112	0.664	.003	28	view →
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
LIHC	OS	Median	All	0.143	0.779	<.001	21	view →
COAD	DFS	Median	All	0.328	0.695	.017	15	view →
LGG	OS	Median	All	0.177	0.909	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	All	0.151	0.660	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

FGF6–LUSC (OS)

Open the LUSC breakdown →